Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Caroline Robert(Institut Gustave Roussy), Adil Daud(University of California, San Francisco), Michael A. Postow(Memorial Sloan Kettering Cancer Center), Hassane M. Zarour(University of Pittsburgh), Roxana Dronca(Dana-Farber Cancer Institute), Jeroen Elassaiss‐Schaap(Merck & Co., Inc., Rahway, NJ, USA (United States)), Omid Hamid(Cedars-Sinai Medical Center), Richard W. Joseph(Daiichi Sankyo (United States)), Wen-Jen Hwu(The University of Texas MD Anderson Cancer Center), Bartosz Chmielowski(UCLA Health), Jeffrey S. Weber(NYU Langone Health), Jedd D. Wolchok(Cornell University), Richard Kefford(Broad Institute), Amita Patnaik(South Texas Accelerated Research Therapeutics), Kevin Gergich(Merck & Co., Inc., Rahway, NJ, USA (United States)), Antoni Ribas(University of California, Los Angeles), F. Stephen Hodi(Harvard University), Anthony M. Joshua(St Vincent's Hospital Sydney), Peter D. Boasberg(Angeles Clinic and Research Institute), Xiaoyun Li(Nanjing University), Robert Iannone(Cornell University), Tara C. Gangadhar(University of Pennsylvania), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Soonmo Peter Kang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Christine Mateus(Centre National de la Recherche Scientifique)

The Lancet

July 15, 2014

Cited by 1,768

|New England Journal of Medicine|2012|12.6k

|New England Journal of Medicine|2012|8k

|New England Journal of Medicine|2011|7.7k

|Science|2017|6.6k

|New England Journal of Medicine|2015|5.9k

Related Papers